aMoon Fund

aMoon Fund is the largest dedicated healthcare and life-sciences fund in Israel, backing what it openly calls global moonshots in biopharma, diagnostics, digital health, and clinical AI. The fund operates with a vast clinical and research network across Israeli hospitals and international partners, which gives portfolio companies real-world validation pathways that smaller funds cannot match. For physician founders, aMoon is one of the few Israeli funds that combines scale, healthcare specialization, and the ambition to fund a company from seed through growth.

The thesis is genuinely cross-modality. aMoon is comfortable with software-driven digital health, AI clinical platforms, biopharma and therapeutics plays, and diagnostic technologies, and the fund tends to back companies with global ambition rather than regional ones. The partner team is staffed with healthcare operators and physicians, which means diligence is clinically literate and the questions are sharp. Founders should expect a long, substantive process rather than a fast yes.

Check sizes run from 5 million to 25 million dollars and the fund operates across seed, Series A, B, C, and growth stages, an unusually wide aperture for a healthcare specialist. aMoon will lead rounds, take board seats, and follow on aggressively when a company is working. Geography is Israel-anchored but globally invested, with substantial United States and European deployment. The fund’s clinical network is part of the value proposition, and physician founders can use it for real-world validation.

The team is built around partners with deep healthcare operating histories, supported by physicians-in-residence and a research function that shapes thesis development. Diligence is rigorous and clinically grounded.

Approach aMoon when you have a clinically credible product, a serious team, and global ambition. Pure consumer-wellness plays without clinical evidence will not get traction; the fund is built for medicine, not lifestyle. Warm introductions from Israeli healthcare operators, United States health-system executives, or partners at other healthtech-specialist funds are the most reliable path in. The fund also engages with academic medical centers and is known to physician founders through clinical networks. Time the conversation when you have clinical evidence ready, a regulatory plan, and a real round forming. Pre-seed founders should consider the fund’s seed-stage activity but understand that aMoon’s center of gravity is at Series A and beyond, and the diligence bar even at the early stage reflects that.